CFM
BIIB icon

Catalyst Funds Management’s Biogen BIIB Stock Holding History

Catalyst Funds Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46M Sell
11,400
-570
-5% -$109K 0.14% 162
2026
Q1 		$2.19M Buy
11,970
+570
+5% +$105K 0.37% 68
2025
Q4 		$2.01M Buy
+11,400
New +$1.86M 0.47% 47
2024
Q4 		– Sell
-600
Closed -$116K – 428
2024
Q3 		$116K Buy
+600
New +$126K 0.03% 456

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Catalyst Funds Management's BIIB Position: Q2 2026 in Review

Catalyst Funds Management reduced its Biogen (BIIB) stake by 4.8% in Q2 2026, selling an estimated $109K and leaving 11,400 shares worth $2.46M. The position accounts for 0.14% of the portfolio, ranked #162.

Catalyst Funds Management first reported a position in BIIB in Q3 2024 and has held it in 4 quarters since. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Catalyst Funds Management held 11,400 shares of Biogen worth $2.46M as of Q2 2026.
  • Catalyst Funds Management sold 570 Biogen shares in Q2 2026, an estimated $109K.
  • Biogen made up 0.14% of Catalyst Funds Management's portfolio in Q2 2026, its #162 holding.
  • Catalyst Funds Management first reported a position in Biogen in Q3 2024 and has held it in 4 quarters since.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.